LAV | RoundOS

Activity in this selectionlilly-asia-ventures-lav-3b865817

By stage

Seed1

Series A1

Series B1

Series C+1

Biotech4

China2

United States2

4 in this selection

May 18

Develops novel therapeutics for immune mediated diseases

$50MSeries C

Role not disclosed

Apr 3

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B

Role not disclosed

Mar 18

Develops next-generation T-cell engager therapies for cancer and autoimmune diseases

Role not disclosed

Jan 14

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1

Role not disclosed